Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — FY2025 Earnings Presentation

20 slides from Day One Biopharmaceuticals's earnings presentation, Feb 24, 2026

  1. Slide 1: Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress

    FEBRUARY 2026 Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc

  3. Slide 3: Agenda & Day One Participants

    Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM 3-Year Data Summary Michael Vasconcelles (Head of R&D) R&D Overview Michael Vasconcelles (Head of R&D) Financial Performance Charles York (Chief Operating & Chief Financial Officer) Q&A Session All Partici

  4. Slide 4: Opening Remarks

    Opening Remarks Jeremy Bender Chief Executive Officer

  5. Slide 5: Q4 & FY 2025 – A Transformational Year For Day One

    Q4 & FY 2025 – A Transformational Year For Day One EMA: European Medicines Agency 1 Represents the comparison of full year 2024 (April 2024 approval) to full year 2025. 2 Regulatory submission process executed by Ipsen. 3 Represents cash, cash equivalents and short-term investments as of December 31

  6. Slide 6: OJEMDA 3-Year Data Summary

    OJEMDA 3-Year Data Summary Michael Vasconcelles Head of R&D

  7. Slide 7: Consistent Safety Profile Through Years of FIREFLY-1 Follow-Up

    Consistent Safety Profile Through 3 Years of FIREFLY-1 Follow-Up June 6, 2025 data cutoff. Adverse events were cumulative events from day 1 to the earliest of (last dose + 30 days, start date of subsequent anticancer treatment, data cut, end of study). *TRAEs reported at grade ≥3 in ≥5% of patients.

  8. Slide 8: Meaningful and Durable Responses Maintained with Extended Follow-Up

    Meaningful and Durable Responses Maintained with Extended Follow-Up June 6, 2025 data cutoff. *1 patient of 77 had a target lesion not meeting the minimum size at baseline per IRC. †ORR for RAPNO included MRs (i.e., ORR=CR+PR+MR). For CR, PR, and MR, confirmation of response by a subsequent scan app

  9. Slide 9: Endpoints Designed to Reflect Real-World Treatment Decisions

    Endpoints Designed to Reflect Real-World Treatment Decisions June 6, 2025 data cutoff. *A cycle was counted if a patient had at least 1 dose in a cycle; patients were treated for a planned period of 26 cycles, after which they could continue tovorafenib or opt to enter an observation period. †1 pati

  10. Slide 10: Clinical Decision-Making Extends Beyond Radiographic PFS in pLGG

    Clinical Decision-Making Extends Beyond Radiographic PFS in pLGG June 6, 2025 data cutoff. *1 patient of 77 had a target lesion not meeting the minimum size at baseline per IRC. †Time to next treatment: an exploratory composite endpoint of time from the date of the first tovorafenib dose to the star

  11. Slide 11: OJEMDA Performance

    OJEMDA Performance Lauren Merendino Chief Commercial Officer

  12. Slide 12: Commercial Execution and Clinical Impact Driving Strong Revenue Growth

    Commercial Execution and Clinical Impact Driving Strong Revenue Growth ~36% Q2 Q3 Q4 Q1 Q2 Q3 Q4 2024 2025 OJEMDA Net Product Revenue $155.4M (+172%)1 in 2025 CQGR Launch $52.8 (+37%)2 $Millions OJEMDA Prescriptions (TRx) 4,635 (+181%)1 in 2025 ~34% Q2 Q3 Q4 Q1 Q2 Q3 Q4 2024 2025 CQGR Launch 1,394 (

  13. Slide 13: Commercial Execution Driving Strong 2026 OJEMDA Outlook

    Commercial Execution Driving Strong 2026 OJEMDA Outlook >50% growth represents the comparison of 2025 to the midpoint of 2026 U.S. net product revenue guidance. 1 2024 net revenue included approximately $3.0M of revenue associated with Ex-U.S. sales. FF-1 3-Year Follow-Up Data Fuels Expected 2026 Gr

  14. Slide 14: Our Strategy: Focused Execution to Solidify OJEMDA as 2L Standard of Care

    Our Strategy: Focused Execution to Solidify OJEMDA as 2L Standard of Care * On label patients only. Drive New Patient Starts Optimize Persistence Increase depth of prescribing through continued evidence generation that reinforces how OJEMDA’s clinical profile and benefits align with attributes physi

  15. Slide 15: R&D Overview

    R&D Overview Michael Vasconcelles Head of R&D

  16. Slide 16: Emi-Le Program Overview

    Emi-Le Program Overview 1 Adenoid Cystic Carcinoma Research Foundation, 2 includes both frontline and relapsed ACC. ACC patient population1,2 Investigational B7-H4-targeted ADC Mechanism and modality well matched to ACC biology due to highly and uniformly overexpressed B7-H4 Evidence of monotherapy

  17. Slide 17: DAY301 Program Overview

    DAY301 Program Overview 1 Damelin M, et al. Sci Transl Med. 2017;9(372):eaag2611, 2 Devang N, et al. Adv Protein Chem Struct Biol. 2021;124:121–185, 3 Dessaux C, et al. Oncogene. 2024;43(26):1973–1984; 4 https://www.proteinatlas.org/ Accessed May 2025, 5 Lhoumeau A-C, et al. Cell Cycle. 2011;10(8):1

  18. Slide 18: Financial Performance

    Financial Performance Charles York Chief Operating Officer & Chief Financial Officer

  19. Slide 19: Fourth Quarter & Full Year 2025 Financial Results

    All financial information is unaudited. 1 Includes stock-based compensation expense of $3.4 million and $14.2 million for the three and twelve months ended 12/31/25, and $3.5 million and $16.7 million for the three month and twelve months ended 12/31/24. 2 Includes stock-based compensation expense o

  20. Slide 20: Thank You

    Thank You

Day One Biopharmaceuticals — FY2025 Earnings Presentation on 6ix